Preventive strategies for septic complications of acute pancreatitis.
The diagram of the mortality of acute pancreatitis is characterized by two distinct peaks, in a similar manner to other generalized acute inflammatory responses. In the first phase, which is characterized by "hyper-inflammatory" mechanisms, death occurs due to overwhelming SIRS and subsequent multi-organ failure. The second peak of death is usually detected much later, at least two weeks after the onset of acute pancreatitis. Infection in necrotising pancreatitis is frequently observed in this so-called "compensatory antiinflammatory" phase. Since there has been no effective therapy evolved to prevent the activation of inflammatory and proteolytic cascades, the treatment of acute pancreatitis is merely symptomatic. Adequate fluid resuscitation and analgesia are the mainstays of treatment. In case of development of multi-organ failure, extensive medical and ventilatory supportive therapy is usually necessary. However, recent studies suggested certain methods might decrease the incidence of infection in pancreatic necrosis, which is usually due to bacterial translocation from the gut. Numerous attempts have been published in the literature to decrease the frequency of septic complications. Furthermore, the outcome of studies favouring antibiotic prophylaxis in acute pancreatitis were debatable. The development of multi-resistant strains of Gram-positive bacteria and Candida, due to long-term antibiotic use, is a strong argument against the indication of prophylactic antibiotic use. Recently, various clinical studies aimed to decrease bacterial translocation, including probiotic use and enteral feeding as part of the treatment. This paper provides a systematic review on data available in the evidence based literature on the use of antibiotics and the role of alternative and supportive therapy in the treatment of severe acute pancreatitis.
Oláh
A
A
Department of Surgery, Petz Aladár Teaching Hospital, Gyor, Hungary. olaha@petz.gyor.hu
Pardavi
G
G
Belágyi
T
T
Romics
L
L
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D010180:Pancreatectomy / Q000379:methods; D010195:Pancreatitis / Q000150:complications; D019283:Pancreatitis, Acute Necrotizing / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D018805:Sepsis / Q000150:complications / Q000517:prevention & control*; D016019:Survival Analysis; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents